New hope for hepatitis b: experimental combo aims to silence the virus
NCT ID NCT05612581
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested two experimental drugs, tobevibart and elebsiran, alone or with standard treatments, in 33 adults with chronic hepatitis B. The goal was to see if these combinations could safely suppress the virus and reduce hepatitis B surface antigen levels. The study is part of a larger effort to find better treatments for this long-term liver infection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tobevibart (VIR-3434) and Elebsiran (VIR-2218) injections, plus standard oral tenofovir and peginterferon
What this could lead to
If successful, this could point toward a more effective combination therapy to control chronic hepatitis B and reduce the need for lifelong medication.
What could go wrong
This is an early-phase trial with only 33 participants, so results may not apply broadly. The treatments may not achieve lasting virus suppression or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS B， CHRONIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigative Site
Clichy, 92110, France
-
Investigative Site
Nice, 06200, France
-
Investigative Site
Rennes, 35000, France
-
Investigative Site
Toulouse, 31000, France
-
Investigative Site
Hong Kong, Sha Tin, Hong Kong
-
Investigative Site
Hong Kong, Hong Kong
-
Investigative Site
Chisinau, MD 2025, Moldova
-
Investigative Site
Bucharest, 021105, Romania
-
Investigative Site
Busan, 49241, South Korea
-
Investigative Site
Seoul, 5505, South Korea
-
Investigative Site
Yangsan, 50612, South Korea
-
Investigative Site
Glasgow, G4 0SF, United Kingdom
-
Investigative Site
London, EC1A 7BE, United Kingdom
-
Investigative Site
London, SE5 9RS, United Kingdom
-
Investigative Site
Manchester, M8 5RB, United Kingdom